SFTA2 and Alzheimer disease: As a consequence, determination of possibly age-dependent alterations of SP-G expression, predominantly in the hippocampus, combined with the detection of the neuropathological hallmarks of AD, e.g., tau hyperphosphorylation (for reviews see [19,20]) and β-amyloidosis (for reviews see [21,22,23]), are warranted.